Merck, J&J Head To Arbitration Over Remicade Deal

Law360, New York (September 8, 2010, 12:55 PM EDT) -- A dispute over whether Merck & Co. Inc. obtained rights to market two Johnson & Johnson arthritis drugs in its merger with Schering-Plough Corp. is slated to go before an arbitration panel later in September.

Merck said in a regulatory filing Tuesday that the hearing would take place before a three-judge panel late this month in New York City and is expected to last 12 days. A decision is expected 20 days after the end of the hearing, it said.

Johnson & Johnson requested the arbitration...
To view the full article, register now.